Psoriatic Arthritis Therapeutics Market to Surpass US$ 24.2 Billion by 2031, Expanding at 8.0% CAGR

The global psoriatic arthritis therapeutics market is witnessing steady expansion, driven by the increasing prevalence of psoriatic arthritis and growing demand for effective treatment options. Psoriatic arthritis is a chronic inflammatory condition associated with psoriasis that affects the joints, skin, and other parts of the body. The treatment landscape includes biologics, conventional disease-modifying antirheumatic drugs (DMARDs), targeted synthetic therapies, and nonsteroidal anti-inflammatory drugs. Advances in immunology and biotechnology have significantly improved treatment approaches, particularly for patients with moderate to severe conditions. Interleukin inhibitors and tumor necrosis factor (TNF) inhibitors have gained considerable attention due to their effectiveness in controlling inflammation and managing disease progression. Increasing awareness, improved diagnostic capabilities, and the availability of advanced pharmaceutical therapies are further supporting market development.

👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=61917

Market Size and Growth

The global psoriatic arthritis therapeutics market was valued at US$ 10.8 billion in 2021 and is projected to expand at a compound annual growth rate (CAGR) of 8.0% from 2022 to 2031, reaching more than US$ 24.2 billion by the end of 2031. Growing disease prevalence, increasing healthcare expenditure, and rising adoption of biologic therapies are among the major factors supporting market growth. Pharmaceutical companies are investing in research and development to introduce innovative medicines that provide improved efficacy, longer-lasting symptom relief, and better patient outcomes. The development of targeted therapies, biosimilars, and oral treatment alternatives is also creating new commercial opportunities. Furthermore, increasing access to specialist healthcare services and improved reimbursement coverage in developed markets are expected to encourage treatment adoption during the forecast period.

Market Segmentation

The psoriatic arthritis therapeutics market is segmented by drug class, route of administration, and distribution channel. Based on drug class, the market includes TNF inhibitors, interleukin inhibitors, Janus kinase (JAK) inhibitors, phosphodiesterase 4 (PDE4) inhibitors, and other therapeutic categories. TNF inhibitors held the largest market share in 2021, supported by their established clinical use, treatment effectiveness, and widespread adoption. Interleukin inhibitors are gaining momentum due to advances in targeted immunological treatments. By route of administration, the market is divided into oral, parenteral, and topical categories. The parenteral segment dominated the market in 2021, primarily due to the extensive use of injectable biologic medicines administered through intravenous and subcutaneous routes. In terms of distribution channel, hospital pharmacies accounted for the leading share, supported by the high cost and specialist supervision associated with biologic treatments. Retail and online pharmacies are also contributing to improving medicine accessibility.

Regional Analysis

North America is expected to remain a highly lucrative regional market through 2031, driven by the high prevalence of psoriatic arthritis, established healthcare infrastructure, favorable access to advanced biologics, and strong pharmaceutical research capabilities. The United States represents a major contributor due to its advanced treatment landscape and availability of innovative medicines. Asia Pacific is anticipated to register substantial growth during the forecast period, supported by rising disease awareness, improving healthcare infrastructure, increasing diagnostic rates, and expanding access to pharmaceutical treatments in China and India. Japan, Australia, and New Zealand also offer opportunities through established healthcare systems and growing adoption of biologic therapies. Europe is expected to maintain a significant market position, supported by the presence of leading biopharmaceutical companies, high healthcare expenditure, and increasing adoption of targeted treatments in Germany, France, and other major economies. Latin America is also expected to experience growth due to improving purchasing power, expanding healthcare access, and increasing availability of biologic and biosimilar medicines.

Competitive Landscape

The global psoriatic arthritis therapeutics market is characterized by the presence of established pharmaceutical and biotechnology companies competing through product innovation, clinical research, strategic collaborations, and geographic expansion. Major players include AbbVie, Inc., Janssen Pharmaceutical NV, Novartis AG, Amgen, Inc., Celgene Corporation, Eli Lilly and Company, Bristol Myers Squibb, and UCB S.A. These companies are focusing on developing next-generation biologics, targeted synthetic drugs, and therapies designed to address unmet medical needs among patients who do not respond adequately to existing treatments. Clinical trial investments, regulatory approvals, product launches, licensing agreements, and partnerships are important strategies for strengthening market positions. The growing biosimilar landscape is also influencing competition by creating additional treatment options and potentially improving affordability.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Media Contact: 

Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY - 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453